Clinical Research Directory
Browse clinical research sites, groups, and studies.
LH-Guided Recombinant LH Supplementation in Women Undergoing IVF/ICSI
Sponsor: Stella Maris Women and Children Hospital
Summary
The goal of this observational study is to evaluate the relationship between luteinizing hormone (LH)-guided recombinant LH supplementation and IVF outcomes in women aged 21-45 years undergoing their first IVF/ICSI cycle using a gonadotropin-releasing hormone (GnRH) antagonist protocol. The main questions it aims to answer are: * Is LH-guided recombinant LH supplementation associated with a higher number of good-quality blastocysts? * Is LH-guided recombinant LH supplementation associated with a higher clinical pregnancy rate? Researchers will compare two groups of women: Group A (LH-Guided Supplementation): Women with serum LH levels below 1.2 mIU/mL on menstrual cycle day 2 or stimulation day 5 (corresponding to menstrual cycle day 6) who received recombinant LH supplementation at 75 IU/day until ovulation triggering. Group B (No LH Supplementation): Women with serum LH levels of 1.2 mIU/mL or higher at both assessments who underwent standard ovarian stimulation without recombinant LH supplementation.
Official title: Day-6 LH-Guided Recombinant LH Supplementation and IVF Outcomes in GnRH Antagonist Cycles: A Retrospective Cohort Study
Key Details
Gender
FEMALE
Age Range
21 Years - 45 Years
Study Type
OBSERVATIONAL
Enrollment
395
Start Date
2023-01-01
Completion Date
2023-12-31
Last Updated
2026-11-12
Healthy Volunteers
Not specified
Locations (1)
RSIA Stella Maris
Medan, North Sumatra, Indonesia